- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04910438
Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. (DepIST-H)
Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Title: Prevalence and longitudinal follow-up over 2 years of anal lesions, HPV infection and associated sexually transmitted infections among men who have sex with men (MSM) in Lomé, Togo (ANRS12400 DepIST-H)
Main objective: To estimate the prevalence and incidence of anal lesions (condyloma, dysplasia and anal cancers) according to HIV status among MSM in Lomé, Togo
Specific objectives :
To estimate the prevalence of HPV infection at baseline (M0) at anal and oropharyngeal sites To describe the persistence of HPV infection at Year 1 and 2 at the anal and oropharyngeal sites To describe the recurrence of anal lesions at Year 1 and 2 To estimate prevalence and incidence of associated STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex Virus type 2, Mycoplasma genitalium, Trichomonas vaginalis) HBV, HCV and syphilis
Methods :
This study is a prospective cohort with a 2-year follow-up of 200 MSM in Lomé (100 HIV- and 100 HIV+). Three data collection systems are integrated into the cohort: (i) clinical data, (ii) socio-behavioural questionnaires, and (iii) biological data.
Sample size: 200 participants (100 HIV+ and 100 HIV-)
Interventions :
Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).
Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.
Statistical analysis methods :
Use of mixed approaches. For quantitative indicators, descriptive analysis techniques, bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or Fisher test for categorical variables) and multivariate analysis (logistic regression).
To estimate the incidence if the STIs, Kaplan-Meier curves, Cox models analyses will be conducted.
As the cohort is open and non-randomized, preliminary analyses will be conducted during the collection.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Didier Koumavi Ekouevi
- Telefonnummer: +228 99 68 67 35
- E-post: didier.ekouevi@gmail.com
Studer Kontakt Backup
- Navn: Arnold Sadio
- E-post: sadioarnold@gmail.com
Studiesteder
-
-
-
Lomé, Å gå
- Rekruttering
- ONG, Espoir Vie Togo
-
Ta kontakt med:
- Ephrem Mensah, MD
- Telefonnummer: +228 90 01 64 11
- E-post: ephremensah@hotmail.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Being a male aged 18 or over
- Self-reporting as being a MSM
- Wishing to be part of a regular clinical follow-up
- Agreeing to participate in the study and signing the informed consent form
- Live in Lomé
- Having had anal intercourse within the past six months prior to inclusion visit
- Regardless of HIV status (infected or not)
- Whether or not the participant has already taken antiretrovirals
Exclusion Criteria:
- Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or sexually transmitted infections (CohMSM ANRS 12324-EF cohort of Lomé)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Prevalence at inclusion of anal lesions
Tidsramme: at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Prevalence of anal lesions at baseline
Tidsramme: at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
Incidence of anal lesions
Tidsramme: at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the number of worsening events of anal cytological lesions
Tidsramme: at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the proportion of recurrence of anal lesions
Tidsramme: at 12 month and 24 month
|
According to HIV status among MSM who received available treatment, in Lomé, Togo
|
at 12 month and 24 month
|
Prevalence of HPV infections
Tidsramme: at Day 0
|
at Day 0
|
|
Incidence of HPV infection
Tidsramme: at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of persistent HPV infections
Tidsramme: at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of clearance of HPV infections
Tidsramme: at 12 month and 24 month
|
in the same individual, on anal and oral specimens, based on HIV status.
|
at 12 month and 24 month
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
Tidsramme: At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
Tidsramme: At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Determination of different Chlamydia trachomatis strains
Tidsramme: At Day 0
|
At Day 0
|
|
Determination of antibiotic resistance profiles for Neisseria gonorrhoeae, Mycoplasma genitalium and Chlamydia trachomatis
Tidsramme: At Day 0
|
According to HIV status
|
At Day 0
|
Incidence of HIV
Tidsramme: at 12 month and 24 month
|
at 12 month and 24 month
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Charlotte Charpentier, Hôpital Bichat Claude Bernard, Paris, France
- Hovedetterforsker: Didier Ekouevi, Lomé University, Togo
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ANRS 12400 DepIST-H
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of Colorado, DenverUniversity of IowaFullførtHealth Care Associated Infection | HåndhygieneForente stater
-
Aionx, Inc.UkjentHealthcare Associated Infection
Kliniske studier på STIs screening and care
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RekrutteringFørste episode psykose (FEP) | Klinisk høy risiko for psykose (CHR)Forente stater
-
Karolinska InstitutetRekrutteringBrystneoplasma, treningSverige
-
Northwell HealthNational Institute on Aging (NIA)Aktiv, ikke rekrutterende
-
Northwell HealthNational Institute on Aging (NIA)Aktiv, ikke rekrutterende
-
Centre hospitalier de l'Université de Montréal...Pentax MedicalFullførtTykktarmskreft | Polypper av tykktarmCanada